Target intelligence / Profile preview

5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR)

Target
MTR
Molecular classification
Enzyme, Methyltransferase, Transferase
01

Overview

5-methyltetrahydrofolate-homocysteine S-methyltransferase, commonly known as methionine synthase (MTR), is a vital cytoplasmic enzyme that catalyzes the transfer of a methyl group from 5-methyltetrahydrofolate to L-homocysteine, yielding tetrahydrofolate and L-methionine. This reaction represents a critical junction linking the folate and methionine cycles, which are essential for DNA synthesis, nucleotide production, and the generation of S-adenosylmethionine (SAM)—the primary methyl donor for cellular methylation reactions. MTR requires methylcobalamin (a form of vitamin B12) as an essential cofactor to facilitate this methyl transfer.

In clinical medicine, MTR is a well-known target of nitrous oxide, an anesthetic gas that irreversibly inactivates the enzyme by oxidizing its cob(I)alamin cofactor, potentially leading to functional vitamin B12 deficiency, megaloblastic anemia, and neurotoxicity. Conversely, cobalamin supplements such as cyanocobalamin and mecobalamin are administered to support or restore MTR activity in deficiency states. Additionally, MTR has emerged as a potential therapeutic target in oncology, where its inhibition is being explored to exploit the 'methyl folate trap' and disrupt cancer cell proliferation.

Other names
Methionine synthaseMSCobalamin-dependent methionine synthase5-methyltetrahydrofolate-homocysteine methyltransferaseTetrahydropteroylglutamate methyltransferaseVitamin B12 methyltransferasecblGMetH
02

Mechanism of action

Nitrous oxide irreversibly inactivates methionine synthase by oxidizing the essential cob(I)alamin cofactor to the inactive cob(II)alamin state, disrupting the folate and methionine cycles. Cobalamin derivatives act as cofactors or precursors to the active methylcobalamin cofactor, restoring enzyme activity in deficiency states.

03

Biological functions

Methionine biosynthesisHomocysteine remethylationFolate cycle regulationOne-carbon metabolismDNA methylation
04

Disease associations

Megaloblastic anemiaHomocystinuriaCardiovascular diseaseNeural tube defectsCancerNeurodegenerative diseaseCognitive impairment
05

Safety considerations

Nitrous oxide-induced myelopathy (subacute combined degeneration of the spinal cord)Megaloblastic anemiaHyperhomocysteinemiaNeurotoxicityTeratogenicity (neural tube defects)
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Homocysteine levelsVitamin B12 levelsFolate levelsMean corpuscular volumeMTR gene polymorphisms

Beyond the preview

Go deeper on 5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call